PMID- 23464623
OWN - NLM
STAT- MEDLINE
DCOM- 20140311
LR  - 20161125
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 9
DP  - 2013 Sep
TI  - Preferences for medication attributes among patients with type 2 diabetes 
      mellitus in the UK.
PG  - 802-9
LID - 10.1111/dom.12091 [doi]
AB  - AIM: To examine preferences for oral medication attributes among participants 
      with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a 
      discrete choice experiment (DCE). METHODS: A web-based DCE was administered where 
      participants indicated which medication they preferred from two different 
      hypothetical oral anti-diabetic (OAD) medication profiles, each composed of 
      differing levels of seven attributes (efficacy, hypoglycaemic events, weight 
      change, gastrointestinal/nausea side effects, urinary tract infection and genital 
      infection, blood pressure and cardiovascular risk) for 20 sets of pair-wise 
      comparisons. A random effects multinomial logit regression model was used to 
      estimate the preference weight (PW) for each of the attribute levels, and the 
      relative importance (RI) of each attribute was calculated. Analyses were 
      conducted for the overall sample and for medication and gender subgroups. 
      RESULTS: The final sample included 100 participants with a mean age of 62.9 (SD 
      11.1) years and comparable numbers of participants of each gender (51% male, 49% 
      female). The majority of the participants were White-British (92%). The total PW 
      and corresponding RI were highest for four of the seven attributes: hypoglycaemic 
      events (PW = 1.98; RI = 24.7%), weight change (PW = 1.65; RI = 20.6%), 
      gastrointestinal/nausea side effects (PW = 1.49; RI = 18.6%) and efficacy 
      (PW = 1.44; RI = 18.0%). The RI values differed for some attributes across gender 
      and number of current T2DM medication subgroups. CONCLUSION: The results suggest 
      that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are 
      of primary importance to patients in their OAD preferences in T2DM. These four 
      attributes comprised over 80% of the RI.
CI  - (c) 2013 Blackwell Publishing Ltd.
FAU - Gelhorn, H L
AU  - Gelhorn HL
AD  - United BioSource Corporation, Bethesda, MD, USA. 
      heather.gelhorn@unitedbiosource.com
FAU - Stringer, S M
AU  - Stringer SM
FAU - Brooks, A
AU  - Brooks A
FAU - Thompson, C
AU  - Thompson C
FAU - Monz, B U
AU  - Monz BU
FAU - Boye, K S
AU  - Boye KS
FAU - Hach, T
AU  - Hach T
FAU - Lund, S S
AU  - Lund SS
FAU - Palencia, R
AU  - Palencia R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130407
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Cardiovascular Diseases/*chemically induced/psychology
MH  - *Choice Behavior
MH  - Decision Making
MH  - Diabetes Mellitus, Type 2/*drug therapy/psychology
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/psychology
MH  - Humans
MH  - Hypoglycemia/*chemically induced/psychology
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Internet
MH  - Logistic Models
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - *Patient Preference
MH  - Pilot Projects
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - United Kingdom/epidemiology
MH  - Weight Gain/drug effects
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - discrete choice experiment
OT  - patient preference
OT  - type 2 diabetes
EDAT- 2013/03/08 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/03/08 06:00
PHST- 2012/12/17 00:00 [received]
PHST- 2013/01/20 00:00 [revised]
PHST- 2013/03/03 00:00 [accepted]
PHST- 2013/03/08 06:00 [entrez]
PHST- 2013/03/08 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.1111/dom.12091 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Sep;15(9):802-9. doi: 10.1111/dom.12091. Epub 2013 Apr 
      7.